Can Plaquenil (hydroxychloroquine) cause leukopenia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Plaquenil Cause Leukopenia?

Yes, Plaquenil (hydroxychloroquine) can cause leukopenia, though this is a rare hematologic adverse effect that requires monitoring during prolonged therapy.

Hematologic Toxicity Profile

The FDA drug label explicitly lists leukopenia among the blood and lymphatic system disorders associated with hydroxychloroquine, alongside other cytopenias including agranulocytosis, aplastic anemia, and thrombocytopenia 1. Periodic blood cell counts should be performed if patients are given prolonged therapy, and if any severe blood disorder such as leukopenia appears that is not attributable to the disease under treatment, discontinuation of Plaquenil should be considered 1.

Clinical Context and Monitoring

The 2012 American College of Chest Physicians guidelines note that antimalarial agents like hydroxychloroquine may cause hematologic effects, though the primary toxicity concerns focus on ocular, cardiac, and myopathic complications 2. The drug label emphasizes that antimalarial compounds should be used with caution in patients with blood disorders 1.

Monitoring Recommendations:

  • Perform periodic complete blood counts during prolonged therapy 1
  • Evaluate for severe blood disorders including leukopenia that cannot be attributed to the underlying disease
  • Consider dose reduction in patients with hepatic or renal disease, as these conditions affect drug clearance and may increase toxicity risk 1

Important Caveats

The distinction between disease-related and drug-related leukopenia is critical. Many conditions treated with hydroxychloroquine (particularly systemic lupus erythematosus) commonly present with leukopenia as part of the disease itself. For example, in hairy cell leukemia patients, 39% present with absolute neutrophil counts <0.5 × 10⁹/L at baseline 3. Therefore, new or worsening leukopenia during hydroxychloroquine therapy requires careful assessment to determine whether it represents drug toxicity or disease progression.

Risk Factors for Hematologic Toxicity:

  • Prolonged therapy duration
  • Concurrent hepatic or renal disease (which increases drug levels) 1
  • Glucose-6-phosphate dehydrogenase (G-6-PD) deficiency (primarily causes hemolysis rather than leukopenia) 1
  • Concurrent use of other myelosuppressive medications

Clinical Action Points

If leukopenia develops during hydroxychloroquine therapy:

  1. Obtain complete blood count with differential to characterize the severity
  2. Assess whether leukopenia is attributable to underlying disease activity versus drug effect
  3. Review concurrent medications that may contribute to myelosuppression
  4. Consider dose reduction or discontinuation if leukopenia is severe and not explained by disease activity 1
  5. Monitor more frequently until blood counts stabilize

The overall incidence of hydroxychloroquine-induced leukopenia is low compared to its more common adverse effects (retinopathy, cardiomyopathy, gastrointestinal symptoms), but vigilance through periodic monitoring remains essential for early detection 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.